Edmond DE Rothschild Holding S.A. Has $82,000 Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT)

Edmond DE Rothschild Holding S.A. lessened its position in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) by 20.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,170 shares of the company’s stock after selling 4,000 shares during the period. Edmond DE Rothschild Holding S.A. owned 0.08% of Nuvectis Pharma worth $82,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the company. Nations Financial Group Inc. IA ADV grew its position in shares of Nuvectis Pharma by 35.0% during the 4th quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company’s stock worth $73,000 after buying an additional 3,500 shares during the period. Baxter Bros Inc. boosted its stake in Nuvectis Pharma by 20.0% during the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock worth $81,000 after acquiring an additional 2,500 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Nuvectis Pharma in the fourth quarter worth $135,000. Forbes J M & Co. LLP increased its stake in Nuvectis Pharma by 21.9% in the fourth quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company’s stock valued at $319,000 after purchasing an additional 10,599 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Nuvectis Pharma by 49.8% during the third quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock valued at $501,000 after purchasing an additional 26,489 shares during the period. Institutional investors own 96.77% of the company’s stock.

Insider Transactions at Nuvectis Pharma

In related news, major shareholder Marlio Charles Mosseri bought 240,000 shares of Nuvectis Pharma stock in a transaction dated Friday, February 7th. The stock was purchased at an average cost of $5.00 per share, with a total value of $1,200,000.00. Following the transaction, the insider now directly owns 2,884,121 shares of the company’s stock, valued at approximately $14,420,605. The trade was a 9.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 35.78% of the company’s stock.

Nuvectis Pharma Stock Up 1.2 %

Shares of Nuvectis Pharma stock opened at $9.46 on Thursday. The company has a market cap of $221.29 million, a PE ratio of -8.16 and a beta of 0.23. The business has a 50 day moving average price of $7.67 and a 200-day moving average price of $6.69. Nuvectis Pharma, Inc. has a 52 week low of $4.44 and a 52 week high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, research analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Maxim Group initiated coverage on Nuvectis Pharma in a research note on Wednesday. They issued a “buy” rating and a $17.00 target price for the company. HC Wainwright reduced their price objective on Nuvectis Pharma from $21.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. Finally, Laidlaw initiated coverage on Nuvectis Pharma in a research report on Monday, March 17th. They set a “buy” rating and a $19.00 target price on the stock.

Nuvectis Pharma Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.